Speciality Medicines IPO Subscription Status Day 1

Here, the Speciality Medicines IPO launched on 20th March 2026. Bidding for the issue will close today, 24th March 2026. The primary aim of the Speciality Medicines IPO is to raise ₹29.14 crores from the market. Also, the Speciality Medicines IPO has received an impressive level of subscription, indicating that the shares will be listed at an impeccable premium. Scroll down to check the Speciality Medicines IPO subscription and details. 

Speciality Medicines IPO Details 

The price band for the Speciality Medicines IPO has been set at ₹117 to ₹124 per share. Let’s segregate the share quota fixed for different categories of investors. 

Speciality Medicines IPO Subscription Status

As of now, the Speciality Medicines IPO has been subscribed to 1.02 times. Of these, 0.00 times are subscribed by retail investors, 0.00 times by non-institutional investors, and 0.00 times by QII (Qualified Institutional Investors).  

The healthy subscription status indicates that investors are expecting higher returns at the time of Speciality Medicines’ IPO listing on 30th March 2026. Speciality Medicines also has a positive outlook behind the fresh issue of 0.24 crore shares, which will raise around Rs 29.14 crores.

Speciality Medicines IPO GMP Today

We know that higher subscription levels drive grey-market premiums for IPOs. Let’s explore the Speciality Medicines IPO GMP for 20th March 2026. 

The grey market premium for this IPO rises to ₹0.00 per share. It indicates that the estimated listing price per share is Rs 124.00. Numerous factors played a pivotal role in this jump in the GMP of Speciality Medicines IPO. These include higher subscription rates, favourable market sentiment, and investors’ positive attitude towards IPOs.

About Speciality Medicines Limited

Speciality Medicines Limited is engaged in the marketing and distribution of finished formulations of speciality pharmaceuticals — including high-cost oral and injectable medications used to treat complex chronic conditions — across both domestic and international markets.

The company’s portfolio includes a wide range of speciality pharmaceutical finished formulations products, which are available in various dosage forms such as tablets, capsules, creams, syrups, eye drops, gels, infusions, inhalers, injections, nasal sprays, ointments, ophthalmic solutions, oral solutions, sachets, and suspensions.

Speciality Medicines Limited Financials

The company’s financial analysis is essential before applying for the Speciality Medicines IPO. See the table for Speciality Medicines Limited’s financials. 

Explanation

Speciality Medicines Limited’s revenue increased by 23.01%, from ₹58.54 crore in March 2024 to ₹36.93 crore in March 2025. Moreover, the company’s PAT increased by 32.52% from ₹8.61 crore in March 2024 to ₹6.06 crore in March 2025.

Technical Indicators

Several technical indicators are available to assess a company’s potential to deliver returns. Use the parameters mentioned below to analyse the technical aspects of the Speciality Medicines IPO.

Speciality Medicines IPO Listing Expectations

Speciality Medicines IPO Highlights: IPO allotment is still pending, as the bid will close today. However, given the current GMP or market sentiment, it is reasonable to expect higher listing gains for the share. A flat 0% in Speciality Medicines, Highlight GMP suggests the estimated listing price per share will be around Rs. 124.

It will provide higher listing gains to investors who applied for this IPO. Also, the financial fundamentals of this business made it the experts’ top long-term recommendation. 

Speciality Medicines IPO Dates

Note: IPO GMP is volatile and depends on market sentiment. Hence, one should conduct their research before investing in it.

Recent Articles

Novus Loyalty IPO GMP Day 3

Novus Loyalty IPO Subscription Status Day 3

Rajputana Stainless IPO Listing Preview

Innovision IPO Listing Preview